Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,320 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: docetaxel Clear all
Terminated Phase 1 Interventional

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

NCT03043989
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Cabazitaxel, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07209189
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, Skull Base Tumors, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00721513
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, docetaxel, fluorouracil, computed tomography, positron emission tomography, quality-of-life assessment, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00075374
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 1 Interventional

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

NCT00440128
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Docetaxel, Casopitant/Docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

NCT03486314
View directory record Official record
Conditions
Advanced Solid Neoplasm
Interventions
Pevonedistat, Rifampin, Docetaxel, Carboplatin, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

NCT00321698
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003587
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Not applicable Interventional Results available

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
Procedure · Drug · Radiation + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Avastin and Taxotere for Esophagogastric Cancer

NCT00137813
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

NCT00217581
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bevacizumab, Docetaxel, Oxaliplatin
Biological · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

AZD2171 to Treat Prostate Cancer

NCT00436956
View directory record Official record
Conditions
Prostate Cancer
Interventions
Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00073866
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

NCT00404066
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-751,871, docetaxel, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 1Phase 2 Interventional

ABI-008 Trial in Patients With Metastatic Breast Cancer

NCT00531271
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABI-008 (nab-docetaxel)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098
View directory record Official record
Conditions
Lung Neoplasm
Interventions
R-DXD, I-DXD, Docetaxel, Rescue Medications, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Lexington, Kentucky • Baltimore, Maryland • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

NCT02387216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
Interventions
MM-121, Docetaxel
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional

Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

NCT00701870
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
24
States / cities
Alhambra, California • Anaheim, California • Burbank, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

NCT00911820
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Stomach Cancer
Interventions
Bevacizumab, Cisplatin, Irinotecan, Docetaxel
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting No phase listed Observational

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

NCT07406282
View directory record Official record
Conditions
Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Darolutamide, Abiraterone acetate, Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

NCT00020046
View directory record Official record
Conditions
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional Results available

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

NCT01253642
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis, Phenelzine Sulfate
Procedure · Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 28, 2026, 3:42 AM EDT